

Long COVID Immune Profiling

NCT06027255

Status	RECRUITING
Phase	Not Applicable
Sponsor	Vanderbilt University Medical Center
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (4)

- Subjects will be 18 years or older, men and women.
- History of confirmed COVID-19 infection (positive contact and symptoms, antigen test or PCR).
- POTS will be defined as the presence of orthostatic tachycardia (>30 bpm) and chronic (>3 months) pre-syncope symptoms.
- Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (>30 bpm) and chronic (>3 months) pre-syncope symptoms. Symptoms occurred within 2 months after COVID infection and persistent until enrollment in the study.

Exclusion (5)

- Individuals with a history of physician diagnosed myocardial infarction, angina, heart failure, stroke, or transient ischemic attack, or who had undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries).
- Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
- Chronic use of steroids, anti-IL6 (omalizumab), anti-TNF-alpha, other immunosuppressants.
- Chronic use of NSAID. Should not enroll if taking without one week prior to blood sampling.
- Treatment with plasmapheresis, IVIG or other immune modulator

Locations (1 total)

Cyndya Shibao, Nashville, Tennessee, United States